A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

abstract：BACKGROUND:It is well known that osteopontin (OPN) plays an important role in tumor progression and that a high OPN expression level in several tumor entities correlates with poor prognosis in cancer patients. However, little is known about the prognostic relevance of the OPN mRNA splice variants. METHODS:We analyzed ...

journal_title：BMC cancer

authors： Hahnel A,Wichmann H,Greither T,Kappler M,Würl P,Kotzsch M,Taubert H,Vordermark D,Bache M

更新日期：2012-04-02 00:00:00

abstract：BACKGROUND:Mutations in the activation segment of the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene are present in approximately 50% of melanomas. The selective BRAF inhibitor vemurafenib has demonstrated significant clinical benefits in patients with melanomas harboring the most common mutations (V600E, V6...

journal_title：BMC cancer

authors： Trudel S,Odolczyk N,Dremaux J,Toffin J,Regnier A,Sevestre H,Zielenkiewicz P,Arnault JP,Gubler B

更新日期：2014-09-29 00:00:00

abstract：BACKGROUND:MicroRNAs (miRNAs) are well recognized as gene regulators and have been implicated in the regulation of development as well as human diseases. miR-143 is located at a fragile site on chromosome 5 frequently deleted in cancer, and has been reported to be down-regulated in several cancers including colon cance...

journal_title：BMC cancer

authors： Gregersen LH,Jacobsen A,Frankel LB,Wen J,Krogh A,Lund AH

更新日期：2012-06-12 00:00:00

abstract：BACKGROUND:Thymosin β10 (Tβ10) expression is associated with malignant phenotypes in many cancers. However, the role and mechanisms of Tβ10 in liver fluke-associated cholangiocarcinoma (CCA) are not fully understood. In this study, we investigated the expression of Tβ10 in CCA tumor tissues and cell lines as well as mo...

journal_title：BMC cancer

authors： Sribenja S,Sawanyawisuth K,Kraiklang R,Wongkham C,Vaeteewoottacharn K,Obchoei S,Yao Q,Wongkham S,Chen C

更新日期：2013-09-23 00:00:00

abstract：BACKGROUND:Medical oncologists continue to use performance status as a proxy for quality of life (QOL) measures, as completion of QOL instruments is perceived as time consuming, may measure aspects of QOL not affected by cancer therapy, and interpretation may be unclear. The pulse oximeter is widely used in clinical pr...

journal_title：BMC cancer

authors： Martins SJ,Ho N,Cavamura SO,Harada CM,Yamamoto CA,Takagaki TY

更新日期：2005-07-06 00:00:00

abstract：BACKGROUND:SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is ...

journal_title：BMC cancer

authors： Al Sarakbi W,Sasi W,Jiang WG,Roberts T,Newbold RF,Mokbel K

更新日期：2009-08-21 00:00:00

abstract：BACKGROUND:Phosphatase of regenerating liver-3 (PRL-3) has deserved attention as a crucial molecule in the multiple steps of metastasis. In the present study, we examined the mechanisms regulating PRL-3 expression, and assessed the clinical potential of PRL-3-targeted therapy in gastric cancer. METHODS:PRL-3 genomic a...

journal_title：BMC cancer

authors： Ooki A,Yamashita K,Kikuchi S,Sakuramoto S,Katada N,Waraya M,Kawamata H,Nishimiya H,Nakamura K,Watanabe M

更新日期：2011-04-06 00:00:00

abstract：BACKGROUND:Photodynamic therapy (PDT) of solid cancers comprises the administration of a photosensitizer followed by illumination of the photosensitizer-replete tumor with laser light. This induces a state of local oxidative stress, culminating in the destruction of tumor tissue and microvasculature and induction of an...

journal_title：BMC cancer

authors： Weijer R,Broekgaarden M,van Golen RF,Bulle E,Nieuwenhuis E,Jongejan A,Moerland PD,van Kampen AH,van Gulik TM,Heger M

更新日期：2015-12-26 00:00:00

abstract：BACKGROUND:Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a benign lymphoid proliferation or malignant lymphoma in patients who have been treated with MTX. MTX withdrawal and observation for a short period should be considered in the initial management of patients who develop LPD while on MTX therapy...

journal_title：BMC cancer

authors： Watanabe S,Manabe O,Hirata K,Oyama-Manabe N,Hattori N,Kikuchi Y,Kobayashi K,Toyonaga T,Tamaki N

更新日期：2016-08-15 00:00:00

abstract：BACKGROUND:Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract and liver and peritoneum are the main sites of recurrence. Ovarian metastases from GIST are very rare. CASE PRESENTATION:A 50 years-old woman was found to have a pelvic mass on transvaginal ultrasound...

journal_title：BMC cancer

authors： De Leo A,Nannini M,Dondi G,Santini D,Urbini M,Gruppioni E,De Iaco P,Perrone AM,Pantaleo MA

更新日期：2018-03-16 00:00:00

abstract：BACKGROUND:With the advent of novel drugs improved overall survival in patients with multiple myeloma, including patients who received up-front autologous stem cell transplantation (ASCT), has been reported from several centers. Here we report on overall survival in a population-based cohort of patients receiving ASCT ...

journal_title：BMC cancer

authors： Tangen JM,Tjønnfjord GE,Gulbrandsen N,Gedde-Dahl T,Stormorken E,Anderson K,Vo CD,Schjesvold FH,For Oslo Myeloma Center.

更新日期：2018-08-08 00:00:00

abstract：BACKGROUND:This paper describes the development of a Cancer Awareness Measure for colorectal (CRC) cancer (Bowel/Colorectal CAMa) (study 1) and presents key results from a population-representative survey using the measure (study 2). METHODS:STUDY 1: Items were taken from the literature and reviewed by expert groups. ...

journal_title：BMC cancer

authors： Power E,Simon A,Juszczyk D,Hiom S,Wardle J

更新日期：2011-08-23 00:00:00

abstract：BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is considered as one of the most aggressive cancers lacking efficient early detection biomarkers. Circulating miRNAs are now being considered to have potency to be used as diagnostic and prognostic biomarkers in different diseases as well as cancers. In case of cancer,...

journal_title：BMC cancer

authors： Chhatriya B,Mukherjee M,Ray S,Sarkar P,Chatterjee S,Nath D,Das K,Goswami S

更新日期：2019-12-03 00:00:00

abstract：BACKGROUND:The predictive value of thymidylate synthase (TS) for clinical sensitivity to pemetrexed-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. This meta-analysis is performed to provide an assessment of whether expression variations of TS are associated with objec...

journal_title：BMC cancer

authors： Wang L,Wang R,Pan Y,Sun Y,Zhang J,Chen H

更新日期：2014-03-19 00:00:00

abstract：:Fasting in disease prevention and treatment has recently become a popular topic, particularly in the context of oncology. Unfortunately, the growing attention paid by the media has created a background of speculations and ambiguous messages. The attitude towards the role of fasting in cancer patients should be very ca...

journal_title：BMC cancer

authors： Caccialanza R,Cereda E,De Lorenzo F,Farina G,Pedrazzoli P,AIOM-SINPE-FAVO Working Group.

更新日期：2018-03-27 00:00:00

abstract：BACKGROUND:Allelic counterparts of biallelically expressed genes display an epigenetic symmetry normally manifested by synchronous replication, different from genes subjected to monoallelic expression, which normally are characterized by an asynchronous mode of replication (well exemplified by the SNRPN imprinted locus...

journal_title：BMC cancer

authors： Dotan ZA,Dotan A,Ramon J,Avivi L

更新日期：2008-12-25 00:00:00

abstract：BACKGROUND:Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with AML ≥65 years marks the potential for hypomethylating agents in elderly AML. Nevertheless the situation ...

journal_title：BMC cancer

authors： Grishina O,Schmoor C,Döhner K,Hackanson B,Lubrich B,May AM,Cieslik C,Müller MJ,Lübbert M

更新日期：2015-05-26 00:00:00

abstract：BACKGROUND:Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests t...

journal_title：BMC cancer

authors： Hicks DG,Janarthanan BR,Vardarajan R,Kulkarni SA,Khoury T,Dim D,Budd GT,Yoder BJ,Tubbs R,Schreeder MT,Estopinal NC,Beck RA,Wang Y,Ring BZ,Seitz RS,Ross DT

更新日期：2010-03-22 00:00:00

abstract：BACKGROUND:We examined 15 years of key performance indicators (KPIs) of the population-based mammography screening programme (PMSP) in Flanders, Belgium. METHODS:Individual screening data were linked to the national cancer registry to obtain oncological follow-up. We benchmarked crude KPI results against KPI-targets s...

journal_title：BMC cancer

authors： Goossens M,De Brabander I,De Grève J,Van Ongeval C,Martens P,Van Limbergen E,Kellen E

更新日期：2019-10-28 00:00:00

abstract：BACKGROUND:Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. CASE PRESENTATIONS:We report a series of four patients, diagnosed with cutaneous T-cell ...

journal_title：BMC cancer

authors： Song JS,Tawa M,Chau NG,Kupper TS,LeBoeuf NR

更新日期：2017-03-16 00:00:00

abstract：BACKGROUND:First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPI...

journal_title：BMC cancer

authors： Miyo M,Kato T,Yoshino T,Yamanaka T,Bando H,Satake H,Yamazaki K,Taniguchi H,Oki E,Kotaka M,Oba K,Miyata Y,Muro K,Komatsu Y,Baba H,Tsuji A

更新日期：2020-07-23 00:00:00

abstract：BACKGROUND:Perturbing Hsp90 chaperone function targets hypoxia inducible factor (HIF) function in a von Hippel-Lindau (VHL) independent manner, and represents an approach to combat the contribution of HIF to cell renal carcinoma (CCRCC) progression. However, clinical trials with the prototypic Hsp90 inhibitor 17-AAG ha...

journal_title：BMC cancer

authors： Bohonowych JE,Peng S,Gopal U,Hance MW,Wing SB,Argraves KM,Lundgren K,Isaacs JS

更新日期：2011-12-15 00:00:00

abstract：BACKGROUND:Persistent high-risk human papillomavirus (HPV) infection is correlated with an increased risk of developing intraepithelial lesion or malignancy (NILM). The aims of the current study is to establish a method named BioPerfectus Multiplex Real Time (BMRT) HPV assay for simultaneous typing and quantifying HPVs...

journal_title：BMC cancer

authors： Sun Z,Zhang R,Liu Z,Liu C,Li X,Zhou W,Yang L,Ruan Q,Zhang X

更新日期：2015-11-06 00:00:00

abstract：BACKGROUND:This study was performed to design a predictive tool that allows the estimation of overall survival (OS) of elderly myeloma patients (aged ≥ 65 years) presenting with myeloma-induced spinal cord compression (SCC). METHODS:One-hundred-and-sixteen patients irradiated for motor deficits of the legs due to myel...

journal_title：BMC cancer

authors： Rades D,Conde-Moreno AJ,Cacicedo J,Veninga T,Gebauer N,Bartscht T,Schild SE

更新日期：2016-04-25 00:00:00

abstract：BACKGROUND:Hypoxia is a common characteristic of solid tumors associated with reduced response to radio- and chemotherapy, therefore increasing the probability of tumor recurrence. The aim of this study was to identify new mechanisms responsible for hypoxia-induced resistance in breast cancer cells. METHODS:MDA-MB-231...

journal_title：BMC cancer

authors： Flamant L,Roegiers E,Pierre M,Hayez A,Sterpin C,De Backer O,Arnould T,Poumay Y,Michiels C

更新日期：2012-09-06 00:00:00

abstract：BACKGROUND:Inhibition of DNA-binding of proteins by small-molecule chemicals holds immense potential in manipulating the activities of DNA-binding proteins. Such a chemical inhibition of DNA-binding of proteins can be used to modulate processes such as replication, transcription, DNA repair and maintenance of epigeneti...

journal_title：BMC cancer

authors： Patel M,Patel D,Datta S,Singh U

更新日期：2020-10-20 00:00:00

abstract：BACKGROUND:Triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER-2), represents a subset of breast cancer with different biologic behaviour. We investigated the clinicopathologic charac...

journal_title：BMC cancer

authors： Rhee J,Han SW,Oh DY,Kim JH,Im SA,Han W,Park IA,Noh DY,Bang YJ,Kim TY

更新日期：2008-10-23 00:00:00

abstract：BACKGROUND:A major impediment in the treatment of ovarian cancer is the relapse of chemotherapy-resistant tumors, which occurs in approximately 25% of patients. A better understanding of the biological mechanisms underlying chemotherapy resistance will improve treatment efficacy through genetic testing and novel therap...

journal_title：BMC cancer

authors： Choi J,Topouza DG,Tarnouskaya A,Nesdoly S,Koti M,Duan QL

更新日期：2020-05-13 00:00:00

abstract：BACKGROUND:Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance. METHODS:Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete response (CR) on BRAF ...

journal_title：BMC cancer

authors： Wheler J,Yelensky R,Falchook G,Kim KB,Hwu P,Tsimberidou AM,Stephens PJ,Hong D,Cronin MT,Kurzrock R

更新日期：2015-02-18 00:00:00

abstract：BACKGROUND:Triple-negative breast cancer (TNBC) exhibit characteristics quite distinct from other kinds of breast cancer, presenting as an aggressive disease--recurring and metastasizing more often than other kinds of breast cancer, without tumor-specific treatment options and accounts for 15% of all types of breast ca...

journal_title：BMC cancer

authors： Kaur P,Nagaraja GM,Zheng H,Gizachew D,Galukande M,Krishnan S,Asea A

更新日期：2012-03-27 00:00:00